Saverio Cinieri
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Pizzamiglio S, Cappelletti V, Cinieri S, Piccart M, Daidone M, Pruneri G, Colombo M, Tagliabue E, Verderio P, Huober J, Nuciforo P, Izquierdo M, Ciniselli C, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clin Cancer Res 2021; 27:6307-6313.
21.09.2021Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
21.09.2021Clin Cancer Res 2021; 27:6307-6313
Pizzamiglio Sara, Cappelletti Vera, Cinieri Saverio, Piccart Martine, Daidone Maria Grazia, Pruneri Giancarlo, Colombo Mario Paolo, Tagliabue Elda, Verderio Paolo, Huober Jens, Nuciforo Paolo, Izquierdo Miguel, Ciniselli Chiara Maura, Triulzi Tiziana, Gargiuli Chiara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Sotiriou Christos, Harbeck Nadia, Di Cosimo Serena
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Di Cosimo S, Daidone M, Piccart M, Izquierdo M, Fumagalli D, Huober J, Saura C, De Santis M, Franzoi M, Cinieri S, Agbor-Tarh D, Porcu L, de Azambuja E. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 2020; 22:115.
27.10.2020Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
27.10.2020Breast Cancer Res 2020; 22:115
Di Cosimo Serena, Daidone Maria Grazia, Piccart Martine, Izquierdo Miguel, Fumagalli Debora, Huober Jens, Saura Cristina, De Santis Maria Carmen, Franzoi Maria Alice, Cinieri Saverio, Agbor-Tarh Dominique, Porcu Luca, de Azambuja Evandro
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Di Cosimo S, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud F, Apolone G, Verderio P, Huober J, Daidone M, Peña L, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019; 118:1-9.
05.07.2019The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
05.07.2019Eur J Cancer 2019; 118:1-9
Di Cosimo Serena, Gori Stefania, Cinieri Saverio, Torri Valter, Baselga José, Piccart Martine, de Braud Filippo G, Apolone Giovanni, Verderio Paolo, Huober Jens, Daidone Maria Grazia, Peña Lorena de la, Triulzi Tiziana, Pizzamiglio Sara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Putzai Lajos, Harbeck Nadia, Izquierdo Miguel, Tagliabue Elda